Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players
NCT ID: NCT01834547
Last Updated: 2013-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2011-05-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacological Cognitive Enhancement
NCT01684306
Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls
NCT02051153
Studying the Role of Brain Molecules for Decision Making
NCT04384562
French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students
NCT02954679
Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
NCT01951508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
HEALTH_SERVICES_RESEARCH
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methylphenidate
Methylphenidate
Drugs use: methylphenidate
40 mg tablets
modafinil
modafinil
Drug use: modafinil
40 mg tablets
caffeine
caffeine
caffeine
400 mg
placebo
placebo
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drugs use: methylphenidate
40 mg tablets
Drug use: modafinil
40 mg tablets
caffeine
400 mg
placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-60 years old
* existence of ELO-number
Exclusion Criteria
* psychiatric diseases (e.g. psychosis, bipolar disorders, etc.) with necessity of using prescription drugs
* addiction of psychoactive substances
* smoker or quitter (\< 5 years)
* use of more than 5 cups of coffee per day
* irregular day-night-rhythm (e.g. shift workers)
18 Years
60 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
K. Lieb
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
K. Lieb
Prof. Dr. med. K. Lieb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry and Psychotherapy
Mainz, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.